Buy 1 kit of Tev-Tropin (somatropin) 5mg HGH Injection Online from Powerall Emporium
Tev-Tropin is part of the Recombinant Human Growth Hormones class and treats Growth Hormone Deficiency. Recombinant human growth hormones are used to treat growth hormone deficiency and to aid in weight gain. They work by stimulating growth in the body. So, Tev-Tropin is only available as a brand-name drug.
Tev-Tropin 5 mg vial contains recombinant somatropin 5 mg and mannitol 30 mg. The 5 mg vial is supplied in a combination package with an accompanying 5 mL vial of diluting solution. The diluent contains bacteriostatic 0.9% sodium chloride injection, USP, (normal saline), 0.9% benzyl alcohol as a preservative, and also water for injection.
SIDE EFFECTS of Tev-Tropin (somatropin)
The following adverse reactions have been observed during appropriate use of somatropin: headaches (children and adults), gynecomastia (children), and pancreatitis (children and adults).
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, the timing of sample collection, concomitant medications, and underlying disease. For these reasons, a comparison of the incidence of antibodies to Tev-Tropin with the incidence of antibodies to other products may be misleading. With respect to growth hormone, antibody binding capacities below 2 mg/L have not been associated with growth attenuation. In some cases, when binding capacity exceeds 2 mg/L, growth attenuation has been observed.
None of the patients with anti-GH antibodies in the clinical studies experienced decreased linear growth response to Tev-Tropin or any other associated adverse event. Injection site reactions (e.g., pain, bruise) occurred in 8 of the 164 treated patients.
Leukemia has been reported in a small number of patients treated with other growth hormone products. It is uncertain whether this risk is related to the pathology of growth hormone deficiency itself, growth hormone therapy, or other associated treatments such as radiation therapy for intracranial tumors.
Instructions for Use [somatropin (rDNA origin)] for Injection
Read the Instructions for Use that come with your Tev-Tropin before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your healthcare provider about your medical condition or treatment. Before you use Tev-Tropin for the first time, make sure your healthcare provider shows you the right way to use it.
Supplies needed for your Tev-Tropin Injection
Tev-Tropin 5mg (See Figure A) containing:
1 vial of Tev-Tropin 5mg growth hormone in a powder, also
1 vial of liquid (diluent) containing Bacteriostatic 0.9% Sodium Chloride Injection, USP (5mL). This is used to mix your Tev-Tropin 5mg.
The recommended dosage of up to 0.1 mg/kg of body weight 3 times per week (up to 0.3 mg/kg/week) should not be exceeded. An acute overdose could cause initial hypoglycemia and subsequent hyperglycemia. Repeated use of doses in excess of those recommended could result in signs and symptoms of gigantism and/or acromegaly consistent with the known effects of excess human growth hormone.
Tev-Tropin 5 mg reconstituted with bacteriostatic 0.9% sodium chloride injection, USP (normal saline) (benzyl alcohol preserved); should not be administered to patients with a known sensitivity to benzyl alcohol (see WARNINGS).
Tev-Tropin 10 mg reconstituted with bacteriostatic water for injection containing 0.33% metacresol should not be used if the patient is allergic to metacresol.
Somatropin should not be used for growth promotion in pediatric patients with closed epiphyses.
Somatropin is contraindicated in patients with active proliferative or also severe non-proliferative diabetic retinopathy.
In general, somatropin is contraindicated in the presence of active malignancy. Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin. Somatropin should be discontinued if there is evidence of recurrent activity. Since growth hormone deficiency may be an early sign of the presence of a pituitary tumor (or, rarely, other brain tumors); the presence of such tumors should be ruled out prior to initiation of treatment. Somatropin should not be used in patients with any evidence of progression or recurrence of an underlying intracranial tumor.
Somatropin is contraindicated in patients with Prader-Willi syndrome who are severely obese or have a severe respiratory impairment (see WARNINGS). Tev-Tropin is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome.